Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: D.Right who wrote (1391)	5/27/1998 11:58:00 AM
From: Peter Singleton	Respond to of 2173

this is old news, but WLA sold $138M of Rezulin Q1 1998, from WLA's 4/28/98 earnings report. Not too shabby for a drug that was approved at the end of January 1997, and launched in March ... I think WLA only has marketing rights in the US, so these would be US sales only. "Rezulin (troglitazone), which recorded sales of $138 million, also contributed to the company's growth. It was the focus of a recent New England Journal of Medicine editorial which noted that Rezulin can address insulin resistance, a fundamental defect in type 2 diabetes. According to the editorial, Rezulin is renewing optimism that type 2 diabetes can be managed effectively. There are currently more than 1 million people on troglitazone therapy worldwide."